

XXIX Congresso Nazionale SIFO
*Società Italiana di Farmacia Ospedaliera
e dei Servizi Farmaceutici delle Aziende Sanitarie*
Napoli, October 12th – 15th 2008

Albumina in rianimazione: oltre il rimpiazzo volemico

dott. Pietro Caironi,
Ist. di Anestesiologia e Rianimazione,
Fondazione IRCCS –
“Ospedale Maggiore Policlinico,
Mangiagalli, Regina Elena” di Milano,
Università degli Studi di Milano



Why do we care for albumin?

Why do we need to care for albumin?

Medline on pubmed

“albumin”: 155.844 items

“hemoglobin”: 125.396 items

last 10 years (1998 – 2008): 57.196 items [37 %]

Everything started during the World War II:

7th december 1941, first case series of 7 patients very severely burned patients injured during the Pearl Harbor attack

Actually, few months before,
the first clinical use of human albumin in traumatic shock

Case 4.—A 20-year-old man was admitted to Walter Reed General Hospital, Washington, D.C., in May 1941, 16 hours after he had sustained bilateral compound comminuted fractures of the tibia and fibula, fractures of five ribs; and associated pleural damage, pneumothorax, and subcutaneous emphysema. He was confused and irrational, with a blood pressure of 76/30 mm. Hg. After he had been given two units of albumin (each approximately 25 gm.), over a 30-minute period, the pressure rose to 106/70 mm. Hg, and two hours later, after insertion of a Kirschner wire, reduction of one of the fractures, and application of a cast, it was 130/80 mm. Hg. Over the next 12 hours, the patient received 1,250 cc. of fluid by mouth and 1,000 cc. of physiologic salt solution subcutaneously. The systolic pressure remained above 130 mm. Hg during this period, with occasional elevations to 150 mm. Hg. There was no evidence of circulatory failure at any time after the administration of the albumin.

Actually, few months before,
the first clinical use of human albumin in traumatic shock

Case 4.—A 20-year-old man was admitted to Walter Reed General Hospital, Washington, D.C., in May 1941, 16 hours after he had sustained **bilateral compound comminuted fractures of the tibia and fibula, fractures of five ribs; and associated pleural damage, pneumothorax, and subcutaneous emphysema.** He was confused and irrational, with a **blood pressure of 76/30 mm. Hg.** After he had been given **two units of albumin (each approximately 25 gm.), over a 30-minute period,** the pressure rose to 106/70 mm. Hg, and two hours later, after insertion of a Kirschner wire, reduction of one of the fractures, and application of a cast, **it was 130/80 mm. Hg.** Over the next 12 hours, the patient received 1,250 cc. of fluid by mouth and 1,000 cc. of physiologic salt solution subcutaneously. The systolic pressure remained above 130 mm. Hg during this period, with occasional elevations to 150 mm. Hg. **There was no evidence of circulatory failure at any time after the administration of the albumin.**



Physiology and pathophysiology




Overview of evidences available



Recent findings besides volume replacement
and new clinical trials...

Albumin structure - peculiarities


Molecular weight: 66.500 Da.

50% of plasmatic protein  responsible for 80%
of oncotic pressure


Important characteristics for the critically ill:

- 1) cystein residuals – thiol groups
- 2) domins I and II
- 3) histidin – imadozole residuals

1) Oxygen radicals and NO scavenger



2) Metabolic transport functions




3) Buffer functions – imidazole residuals

Group	AH	\rightleftharpoons	A ⁻ + H ⁺	pK
Glu Asp	-COOH	\rightarrow	-COO ⁻ + H ⁺	4.4
Lys	-NH ₃ ⁺	\leftarrow	-NH ₂ + H ⁺	10
Arg	$\begin{array}{c} \text{H} \\ \\ \text{-N-C} \\ / \quad \backslash \\ \text{NH}_2^+ \quad \text{NH}_2 \end{array}$	\leftarrow	$\begin{array}{c} \text{H} \\ \\ \text{-N-C} \\ / \quad \backslash \\ \text{NH}_2^+ \quad \text{NH}_2 \end{array}$	H ⁺ 12
<i>net fixed charge -21 mEq/mole</i>				
His	$\begin{array}{c} \text{-CH}_2 \\ \\ \text{+HN} \quad \text{HN} \\ \backslash \quad / \\ \text{N} \end{array}$	\rightleftharpoons	$\begin{array}{c} \text{-CH}_2 \\ \\ \text{N} \quad \text{HN} \\ \backslash \quad / \\ \text{N} \end{array}$	H ⁺ 6.5
<i>16 imidazole residuals – buffer function</i>				
Cys	-SH	\leftarrow	-S ⁻ + H ⁺	8.5
<i>binding function. NO. scavenger</i>				


Which functions are important for the critically ill?

Primary




Oncotic properties


Secondary




Transport



Anti-oxydant



Nitric oxide modulation




Acid base status

What's the real problem for the critically ill ?

Hypoalbuminemia


(↓ plasma concentration, normal values ≈ 40 g/L)
is a symptom resulting from




What's the real problem for the critically ill ?

Hypoalbuminemia

(↓ plasma concentration, normal values ≈ 40 g/L)
is a symptom resulting from

- 
- 1 – decreased absolute content
 - 2 – altered water metabolism
 - 3 – redistribution



Indeed, two main questions:

- Hypoalbuminemia *per se* causes morbidity and/or mortality?
- Do we need to treat it?
What is the best cure for hypoalbuminemia?



Physiology and pathophysiology



Overview of evidences available



Recent findings besides volume replacement
and new clinical trials...


From 1998 to 2003: The era of meta-analysis...

Albumin infusion

Cochrane meta-analysis [1998]

**Human albumin administration in critically ill patients:
systematic review of randomised controlled trials**

Cochrane Injuries Group Albumin Reviewers




Harmful

Wilkes' meta-analysis [2001]

Patient Survival after Human Albumin Administration

A Meta-Analysis of Randomized, Controlled Trials

Mahlon M. Wilkes, PhD, and Roberta J. Navickis, PhD



Indifferent


Vincent's meta-analysis [2003]

**Hypoalbuminemia in Acute Illness: Is There a
Rationale for Intervention?**

A Meta-Analysis of Cohort Studies and Controlled Trials

Jean-Louis Vincent, MD, PhD, FCCM,* Marc-Jacques Dubois, MD,* Roberta J. Navickis, PhD,† and Mahlon M. Wilkes, PhD†

*From the *Department of Intensive Care, Université Libre de Bruxelles, Hôpital Erasme, Brussels, Belgium, and †Hygeia Associates, Grass Valley, California, U.S.A.*



Beneficial

Point of view...

Epidemiology:

“Tomb of intelligence”

Meta-analysis:

“Sacking of tombs”



Reliability of meta-analysis

... finally, a prospective randomized study.

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit

The SAFE Study Investigators*

ABSTRACT

BACKGROUND

It remains uncertain whether the choice of resuscitation fluid for patients in intensive care units (ICUs) affects survival. We conducted a multicenter, randomized, double-blind trial to compare the effect of fluid resuscitation with albumin or saline on mortality in a heterogeneous population of patients in the ICU.

METHODS

We randomly assigned patients who had been admitted to the ICU to receive either 4 percent albumin or normal saline for intravascular-fluid resuscitation during the next 28 days. The primary outcome measure was death from any cause during the 28-day period after randomization.

N Engl J Med 2004;350:2247-56

Prospective, randomized, double-blinded trial

16 ICU (Australia, New Zealand)

Intravascular fluid resuscitation by 4% albumin infusion (*treated group*) or saline NaCl 0.9% infusion (*control group*)

6997 patients { Treated group: 3497 patients
Control group: 3500 patients

Primary outcome:

death from any cause at 28-day period after randomization




Figure 1. Kaplan–Meier Estimates of the Probability of Survival.

P=0.96 for the comparison between patients assigned to receive albumin and those assigned to receive saline.

Dead patients (%)
treated group 20.9% vs
control group 21.1%
(p=0.87)

CONCLUSIONS

In patients in ICU, use of either 4% albumin or normal saline for fluid resuscitation results in **similar outcomes** at 28 day

SAFE study – 2004, subgroup analysis




Figure 2. Relative Risk of Death from Any Cause among All the Patients and among the Patients in the Six Predefined Subgroups.

The size of each symbol indicates the relative number of events in the given group. The horizontal bars represent the confidence intervals (CI). ARDS denotes the acute respiratory distress syndrome.

Treated %

Control %

P

Trauma patients

13.6

10.0

0.06

Severe sepsis patients

30.7

35.3

0.09

ARDS patients

39.3

42.4

0.72

Albumin administration improves organ function in critically ill hypoalbuminemic patients: A prospective, randomized, controlled, pilot study*

Marc-Jacques Dubois, MD, FRCPC; Carlos Orellana-Jimenez, MD; Christian Melot, MD, PhD, Msc (Stat); Daniel De Backer, MD, PhD; Jacques Berre, MD; Marc Leeman, MD, PhD; Serge Brimioulle, MD, PhD; Olivier Appoloni, MD; Jacques Creteur, MD, PhD; Jean-Louis Vincent, MD, PhD, FCCP, FCCM

Crit Care Med 2006;34:2536-40

Prospective, controlled, randomized study

1 institution (Brussels) – 31 beds

100 patients, if < 30 g/L

{	Treated group: 50 patients
	Control group: 50 patients



300 ml + 200 ml 20% albumin, if < 30 g/L
vs. no albumin

Dubois' study - 2006

Table 3. Baseline, last, and delta Sequential Organ Failure Assessment (SOFA) values in control and albumin groups

	Control Group (n = 50)	Albumin Group (n = 50)	p Value
Baseline SOFA	5.7 ± 0.8	6.3 ± 0.8	.31
Last SOFA	4.6 ± 1.2	4.1 ± 1.1	.65
Delta SOFA	1.4 ± 1.1	3.1 ± 1.0	.03

Last SOFA, SOFA score at day 7 or before if patient discharged or died; delta SOFA, difference between baseline and last SOFA.

Data are expressed as mean ± SD.

“The current pilot study also suggests that in the specific group of hypoalbuminemic critically ill patients, albumin may have beneficial effects on organ function, although the exact mechanisms remain undefined”.



Physiology and pathophysiology



Overview of evidences available



Recent findings besides volume replacement
and new clinical trials...

Clinical indications – Recent findings

From evidence-based to individual-based medicine...!

- Patients with peripheral edema during recovery phase
- Patients with traumatic brain injury
- Patients with severe sepsis

ORIGINAL ARTICLE

Saline or Albumin for Fluid Resuscitation in Patients with Traumatic Brain Injury

The SAFE Study Investigators*

ABSTRACT


BACKGROUND

The Saline versus Albumin Fluid Evaluation study suggested that patients with traumatic brain injury resuscitated with albumin had a higher mortality rate than those resuscitated with saline. We conducted a post hoc follow-up study of patients with traumatic brain injury who were enrolled in the study.

METHODS


For patients with traumatic brain injury (i.e., a history of trauma, evidence of head trauma on a computed tomographic [CT] scan, and a score of ≤ 13 on the Glasgow Coma Scale [GCS]), we recorded baseline characteristics from case-report forms, clinical records, and CT scans and determined vital status and functional neurologic outcomes 24 months after randomization.

Patients with traumatic brain injury



“In this post hoc study of critically ill patients with traumatic brain injury, fluid resuscitation with albumin was associated with higher mortality rates than was resuscitation with saline.”

Patients with severe sepsis – [SAFE study]



	Treated %	Control %	P
Trauma patients	13.6	10.0	0.06
Severe sepsis patients	30.7	35.3	0.09
ARDS patients	39.3	42.4	0.72



**Uso dell'albumina nel rimpiazzo volemico
di pazienti con sepsi severa o shock settico
(FARM6JS3R5)**

finanziato dall'Agenzia Italiana del Farmaco
(bando AIFA 2006)

Steering Committee:

Luciano Gattinoni, Pietro Caironi, Antonio Pesenti, Roberto Fumagalli,
Roberto Latini, Serge Masson, Marilena Romero, Gianni Tognoni

Steering Committee


- 1) Istituto di Anestesiologia e Rianimazione, Fondazione IRCCS – “Ospedale Maggiore Policlinico Mangiagalli, Regina Elena” di Milano [Centro Coordinatore]: *L. Gattinoni, P. Caironi*
- 2) Dipartimento di Medicina Perioperatoria e Terapia Intensiva, A.O. San Gerardo di Monza: *A. Pesenti, R. Fumagalli*
- 3) Consorzio Mario Negri Sud, S. Maria Imbaro, Chieti: *G. Tognoni, M. Romero*
- 4) Istituto di Ricerche Farmacologiche Mario Negri, Milano: *R. Latini, S. Masson*

Data and Safety Monitoring Board

P.M. Suter, J.L. Vincent, M.G. Valsecchi, A. Santosuosso

Good Clinical Practice Monitoring

Centro Studi SIFO (Società Italiana di Farmacia Ospedaliera)



Ipotesi

Efficacia della somministrazione di albumina durante sepsi severa o shock settico:



nel rimpiazzo volemico



come correzione dell'ipoalbuminemia
(*funzioni secondarie*)

Obiettivo primario:

Verificare l'ipotesi che il rimpiazzo volémico con l'utilizzo di albumina e il mantenimento della sua concentrazione plasmatica entro un intervallo fisiologico (≥ 30 g/L) migliori la sopravvivenza a 28 e a 90 giorni dalla randomizzazione nello studio in pazienti con sepsi severa o shock settico, rispetto ad un rimpiazzo volémico con l'utilizzo di cristalloidi.

Obiettivi secondari:

Verificare l'ipotesi che il rimpiazzo volémico con l'utilizzo di albumina e il mantenimento della sua concentrazione plasmatica ≥ 30 g/L riduca:

- 1) Il numero e la gravità delle disfunzioni d'organo, come rilevato dal punteggio SOFA (*modificato*);
- 2) la durata della degenza in Terapia Intensiva;
- 3) la durata della degenza ospedaliera.

Disegno dello studio

Pz. con sepsi severa o shock settico

Incannulamento di un vaso arterioso e venoso centrale
(*se non già in sede*)

Randomizzazione

Rimpiazzo volémico
[Rivers]

Albumina

Albumina:
[300 ml al 20% in 3* hr]
+
cristalloidi

Cristalloidi

cristalloidi

dal giorno 1 al giorno 28 (o dimissione dalla TI)

Albumina

Controllare
albuminemia

≥ 30 g/L

< 30 g/L e
 ≥ 25 g/L

< 25 g/L

Nessuna infusione
di Albumina

Infusione di
Albumina:
200 ml al 20%
in 3* ore

Infusione di
Albumina:
300 ml al 20%
in 3* ore

N.B.: quando non disponibile, riferirsi al valore di albuminemia del giorno precedente

dal giorno 1 al giorno 28 (o dimissione dalla TI)


Cristalloidi

Controllare
albuminemia


Se condizioni di estrema gravità
(es.: albuminemia < 15 g/L),
consentita l'infusione di Albumina
[in 3* ore]

**o in un periodo di tempo maggiore (se ritenuto clinicamente più utile), purché l'infusione termini entro il momento della compilazione della scheda giornaliera del giorno successivo*


Conclusions




“**Secondary functions**” may be the most important in critically ill patients



Evidence based: for routine volume replacement in mild critically ill, albumin is not recommended, and in patients with traumatic brain injury should not be employed.



However: in hypoalbuminemic patients, it may be beneficial, especially in patients with peripheral edema during the recovery phase.



In patients with **severe sepsis**, it may be beneficial (see in the next future... ALBIOS study)